Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

11.00
+0.14001.29%
Volume:100.71K
Turnover:1.11M
Market Cap:725.67M
PE:-9.62
High:11.15
Open:10.82
Low:10.81
Close:10.86
52wk High:15.74
52wk Low:2.32
Shares:65.97M
Float Shares:39.39M
Volume Ratio:0.45
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1430
EPS(LYR):-0.1569
ROE:-31.21%
ROA:-20.63%
PB:3.66
PE(LYR):-70.11

Loading ...

Fulcrum’s Pociredir Trial Completion Adds a New Catalyst to the Sickle Cell Investment Story

TIPRANKS
·
Yesterday

Fulcrum Therapeutics Grants 70,000 Stock Options to New Employee

Reuters
·
Feb 07

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 07

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Feb 05

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

TIPRANKS
·
Feb 02

Fulcrum and Kpmg Announce Collaboration to Transform Utility Field Operations and Strengthen Operational Resiliency

THOMSON REUTERS
·
Jan 27

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

TIPRANKS
·
Jan 26

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

TIPRANKS
·
Jan 16

Fulcrum Therapeutics Showcases Pociredir's Promise as Best-in-Class Oral Therapy for Sickle Cell Disease

Reuters
·
Jan 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulcrum Therapeutics (FULC), Teladoc (TDOC) and MDxHealth (MDXH)

TIPRANKS
·
Jan 13

Fulcrum Therapeutics updates strategy on lead sickle cell therapy

TIPRANKS
·
Jan 12

Fulcrum Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Jan 12

JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target

MT Newswires Live
·
Jan 12

Fulcrum Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS
·
Jan 12

Fulcrum Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 10

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 10

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Jan 07

Chief Legal Officer Curt Oltmans Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 18, 2025

Fulcrum Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Dec 12, 2025

RA Capital Management Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 11, 2025